Table 2 Baseline fistula data
CharacteristicPlacebo (n  =  47)Adalimumab 40 mg eow (n  =  30)Adalimumab 40 mg weekly (n  =  40)
Draining cutaneous fistulas,* no (%)
    One30 (63.8)19 (63.3)23 (57.5)
    Two7 (14.9)6 (20.0)7 (17.5)
    Three6 (12.8)1 (3.3)5 (12.5)
    Four4 (8.5)4 (13.3)5 (12.5)
Perianal fistulas,† no (%)
    One29 (64.4)19 (63.3)21 (55.3)
    Two7 (15.6)6 (20.0)7 (18.4)
    Three6 (13.3)1 (3.3)5 (13.2)
    Four3 (6.7)4 (13.3)5 (13.2)
  • *Draining cutaneous fistulas includes perianal fistulas (n  =  113) and abdominal fistulas (n  =  4). †n  =  45 for placebo; n  =  30 for 40 mg adalimumab eow; n  =  38 for 40 mg adalimumab weekly. eow, every other week.